Search
Filter Results
- Resource Type
- Article1
- Database1
- Article Type
- Clinical Trial1
- Randomized Controlled Trial1
- Clinical Study1
- Controlled Clinical Trial1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Arch Gen Psychiatry1
Search Results
Sort by
- DatabaseSummary: Includes over <200> digital periodicals in biology and the health sciences which follow the "open access" funding model-- not charging readers or their institutions for access. The aim is to "increase the visibility and ease of use of open access scientific and scholarly journals thereby promoting their increased usage and impact." Journals must be peer reviewed or have other quality guarantee for inclusion.Digital Access Directory
- ArticleRifkin A, Quitkin F, Kane J, Struve F, Klein DF.Arch Gen Psychiatry. 1978 Apr;35(4):483-9.Of 55 aftercare patients receiving long-term treatment with antipsychotic and antiparkinson (AP) drugs, 37 were switched to being given placebo, and 18 remained on a regimen of procyclidine hydrochloride. The dose of antipsychotic was kept constant. After three weeks extrapyramidal side effects (EPS) developed in 54% of those patients receiving placebo and in none of those receiving procyclidine (P less than .002): Twenty-seven percent of the placebo group had EPS without akinesia, and in the same percentage akinesia developed (P = .003). We believe the risk-benefit ratio favors the routine use of AP drugs for prophylaxis and maintenance so as to avoid misdiagnosing as psychopathology, unspontaneity due to akinesia, and to reduce unreliable pill-taking due to EPS.